# In this edition...

In what appears to be a key scientific advance, Stem Cell Sciences researchers have worked out how to grow rats from rat embryonic stem cells. This is a breakthrough for the drug discovery industry.

Ventracor generated significant sales (\$17 million) of its heart assist device in FY2008 and appears to be a clear number two in the race to market with its second generation LVAD.

We also review thirteen profitable life science companies.

Companies covered: AMT, CLV, COH, CMP, CSL, CST, CTE, ELX, IDT, ITD, PBP, RMD, STC, SRX, TIS, VCR

	Bioshares Portfolio
Year 1 (May '01 - May '02)	21.2%
Year 2 (May '02 - May '03)	-9.4%
Year 3 (May '03 - May '04)	70.0%
Year 4 (May '04 - May '05)	-16.3%
Year 5 (May '05 - May '06)	77.8%
Year 6 (May '06 - May '07)	17.3%
Year 7 (May '07 - May '08)	-36%
Year 8 (May '08 - current)	-8.0%
Cumulative Gain	90%
Av Annual Gain (7 yrs)	17.8%

*Bioshares* is published by Blake Industry & Market Analysis Pty Ltd.

Blake Industry & Market Analysis Pty Ltd ACN 085 334 292 PO Box 193 Richmond Vic 3121 AFS Licence No. **258032** 

Enquiries for *Bioshares* Ph: (03) 9326 5382 Fax: (03) 9329 3350 Email: info@bioshares.com.au

David Blake Ph: (03) 9326 5382 Email: blake@bioshares.com.au Mark Pachacz Ph: (03) 9671 3222 Email: pachacz@bioshares.com.au

Individual Subscriptions (48 issues/year) \$320 (Inc.GST) Edition Number 279 (5 September 2008) ISSN 1443-850X

Copyright 2008 Blake Industry and Market Analysis Pty Ltd. ALL RIGHTS RESERVED. Secondary electronic transmission, photocopying, reproduction or quotation is strictly prohibited without written consent of the publisher.

# Bioshares

5 September 2008 Edition 279

Delivering independent investment research to investors on Australian biotech, pharma and healthcare companies.

# Stem Cell Smarts About To Pay Off

Stem Cell Sciences (STC: 25 cents) has long been respected for its leading expertise and intellectual property position in the stem cell field. Just how the company was going to prosper from that knowledge and from those technology assets in the short to medium term has remained uncertain. However, scientists linked to the company, including Austin Smith, have just announced the development of the technology needed to make transgenic rats from rat-derived embryonic stem cells.

# A Scientific Breakthrough, A Drug Research Breakthrough

This is the first time it has been shown that genetically altered rats will be able to be produced from rat embryonic stem cells. What this allows is the ability to grow rats that have specific genes added or deleted to help in the screening of new pharmaceuticals. Rats have far more genes in common with humans that do mice. Hence the technology represents a breakthrough for drug researchers.

The technology has been used to develop the knock-in (genes added) or knock-out (genes deleted) mice over the last 20 years but to date has been unable to be achieved in rats. There are advantages of using the rat as an animal model in that they are judged as being more predictable of some human diseases, including psychiatric, neurological and cardiovascular diseases.

The market for transgenic mice is estimated at several hundred millions of dollars a year and has helped build highly successful international biotech businesses such as **Deltagen**, **Regeneron** and **Lexicon Pharmaceuticals**. Stem Cell Sciences estimates that the annual global market for transgenic rats for pharmaceutical research could be valued in excess of US\$80 million a year. Stem Cell Sciences plans to license the technology to service providers to the pharmaceutical industry, with potentially a multimillion dollar upfront payment and royalties from sales on offer. The company may control the production of the rat embryonic stem cells in-house. Stem Cell Sciences is aiming to secure licensing arrangements as soon as possible.

What makes the results more compelling is that experiments have been replicated several times in two independent laboratories, validating the discovery. The first transgenic rat using this technology should be produced within 12 months and the technology could be available to pharmaceutical companies within two to three years. It is clearly the largest scientific development for Stem Cell Sciences this year. The breakthrough is expected to be published in a major scientific journal in the next three months. Stem Cell Sciences has filed patents over the rat embryonic stem cells and the culture medium used to grow the cells. With a capitalisation of only \$8 million, and with \$3.7 million in cash at mid-year, Stem Cell Sciences has become a very appealing investment with greater clarity over where medium term revenue growth will be achieved.

Bioshares recommendation: Speculative Buy Class B

Within two years time, Ventracor (VCR: SP 20 cents: Cap. \$62 million) should have its LVAD heart pump approved and on sale in the US market for bridge-to-transplant (BTT) patients. Its device is already approved for use in Europe, parts of Asia and Australia, and the company is generating sales of the device in the US through clinical trials. However, the key region is the US, and with that market rapidly expanding thanks to the approval of competitor **Thoratec's** second generation device, Ventracor is well placed to enter what should be a sizeable US market as the number two player.

# LVAD market accelerating

In April this year, the leading player in the LVAD (left ventricular assist device) space, **Thoratec**, had its second generation LVAD approved by the FDA, the Heartmate II for BTT. As expected, this has had a major positive impact on the LVAD market.

As of April 25 this year, Thoratec had over 1300 patients implanted with its Heartmate II according to its quarterly report. Following approval on April 21 of the Heartmate II in the US, this figure jumped to over 1600 implant devices by the end of June worldwide.

The US accounts for approximately 75% of the global LVAD market, largely due to the reimbursement of the device and procedure, which will be US\$131,000 in 2009. An analyst report from Canaccord Adams estimates that around 750 Heartmate II systems are expected to be sold this year in the US alone, and close to 1300 LVAD systems worldwide by Thoratec generating revenue of just under US\$200 million. This revenue figure is expected to increase to around US\$300 million by 2010.

Thoratec previously had a bulky and awkward first generation system approved (Heartmate XVE) which is still selling. This system weighs just under1.2 kg, has two valves and many moving parts. By comparison the Ventracor LVAD, the VentrAssist, is about one quarter of the weight with no valves and only one moving part. The approval in the US of a significantly more reliable and smaller LVAD, the Thoratec Heartmate II, is quickly opening up the massive potential LVAD market. This is great news for Ventracor, which is two years behind Thoratec with, according to clinical trial results, an even more reliable LVAD.

But there may be even more good news for LVAD players. It's expected that by early to mid 2010, Thoratec will also have its device approved for destination therapy (DT), whereby the device is implanted into patients who have terminal heart disease and are even too sick to be accepted for a heart transplant. This has the potential to create an annual billion dollar market.

The release of a reliable LVAD system into the US market is also beginning to cause a blurring between the BTT and DT classifications. This is an important and understandable trend. Cardiologists can recommend patients for an LVAD if they 'intend' to place them on the transplant list, giving them access now to the newly approved Heartmate II device which is not currently approved for the more ill DT patients. Only about half of the patients on the BTT program are on the transplant list.

There are around 2000 heart transplants conducted each year in the US, and we estimate the BTT market in the US at 4000 devices a year, or around US\$400 million. There is no immediate limit from the number of eligible patients in the US who could benefit from an implanted LVAD, with acceptable estimates of numbers in excess of 100,000 a year. However, realistically, restraints from health budgets and capacities at transplant and cardiac surgery centres will govern a more measured uptake to a market that could reach between US\$800 million - US\$1 billion within five years worldwide.

#### **Device sales**

In the financial year just ended, Ventracor's sales surged, from \$4.9 million in 2007 to \$17.3 million in 2008. The company sold 189 devices and generated a net loss \$25 million. Payment for devices is generally quick, within 30-40 days of sale.

Sales increased to \$2.1 million in Australia and Asia, with predominantly wealthy patients in Hong Kong and India contributing to those sales. In Europe, sales increased significantly by \$4.2 million to \$5.9 million. And in the US, sales increased by \$7.3 million to \$9.3 million.

In Europe, Germany was a significant contributor (around 50% of sales), where the device is sold and the controller is rented, providing an annuity stream to the company. The device sells for a higher price in Europe, at 75,000 Euros. A key factor to increasing the market in Europe is gaining reimbursement in France, which may occur by the end of 2008.

In the US, sales has come through reimbursement from Medicare for devices used in clinical trials. Most people over the age of 65 are covered under the Medicare system and all patients being recruited into the trials must have coverage from payors. Given that the most people for which an LVAD system is suitable for are over the age of 65, explains the appeal of the US for the LVAD market.

It is also important to note that once Ventracor's clinical trials in the US are finished, it can continue to enroll patients (and sell devices) under the Continued Access Protocol. Thoratec has been enrolling around 200 patients a year under this CAP in its DT trial of its Heartmate II device. The CAP system should allow Ventracor to maintain US sales whilst its device is awaiting FDA approval.

#### Clinical trials update

To date more than 325 patients have been implanted with the Ventracor device with the longest surviving patient implanted for just under four years. In the CE Mark Bridge Trial, 33 patients were implanted with an 82% success rate in reaching the goal of survival or transplant at 154 days. In the US BTT trial, 82% of the 28 patients in the feasibility trial survived to the same endpoint at 180 days. This was a better result than the Thoratec Heartmate II US *Cont'd over* 

#### Ventracor cont'd

BTT trial, which achieved a 74% success rate for the same endpoint. That device was approved, even though it did not meet the set goal of 75% success at 180 days.

Ventracor has completed 97 implants (with 52 patient outcomes received so far) in the US BTT trial, with 98 patient outcomes required at which point it will conduct an interim analysis. From that point, either the trial will continue to the planned 140 implants (patient outcomes). However if the data shows the device has sufficiently met endpoints, then the company may be in a position to file the device for BTT approval in the US on the interim data.

The DT trial has fallen behind schedule, with only 46 patients included to date, including the control arm (up from 15 in February), with 225 to be enrolled in total. The reason for slower recruitment rate is that the surgeons have wanted to gain more experience with the BTT implants, before implanting the sicker DT patients. There are two modules in this arm. Module A is recruiting healthier patients and comparing against standard drug therapy. The patients in a more dire health position, some with only weeks to live, are allocated to Module B, where the company's VentrAssist device is being compared against the only LVAD approved for destination therapy in the US, the first generation Heartmate XVE.

#### Comparison with heart transplant

The reliability of LVAD systems and the patient survival records have improved substantially with the introduction of second and third generation systems. Direct comparison data with heart transplant is difficult to obtain with the newer systems because most the data available measures only in the BTT group, up to when the patients either receive a transplant or for 180 days post implant.

Data from the DT trials will also not be a direct comparator, because these are patients who are very ill and ineligible for a heart transplant. Taking that into account, historical data shows that one-year survival rates in heart transplant recipients is around 86%. The Ventracor data of 86% survival at six months indicates that Ventracor's LVAD is gaining ground on heart transplants as measured by short term survival. At three years the survival for a heart transplant is around 77% and there is no data available to compare the Ventracor device, although there are some patients approaching four years with living with the device.

These measures do not include patient comfort. Heart transplant recipients can lead more normal lives although are required to have chronic anti-rejection drug therapy. LVAD systems remain awkward with a percutaneous lead through the skin and a controller having to be worn on a harness set up. Ventracor is working on a fully implantable system, which if successful, has the potential to become a market leading product and increase the appeal and usability of LVAD system. It remains to be seen whether the regulatory approval process can be streamlined with this future advance over the next three years, given the pump itself will remain unchanged.

## **Capital raising**

Ventracor had \$18 million at mid year and is currently seeking to raise additional capital of around \$20 million for the next 12 months of operation. There are expectations that the business should become cash flow positive over the next two to three years. This is a reasonable expectation, with the company's VentrAssist device we anticipate to be approved for use in the US by mid 2010 and given the rapid adoption of the competing second generation Heartmate II device since approval for BTT in April this year.

#### Risks

The risk with all mechanical heart pumps is the expected future success of stem cell therapy. However there will likely be degrees of efficacy of stem cell therapies which remain a number of years away and it's unlikely they will provide a cure-all solution to cardiovascular disease. Stem cell therapy potentially could also be used in conjunction with LVAD therapy to help unload the heart during cell therapy to better facilitate the heart re-growth.

#### Summary

The global market potential for LVADs is arguably somewhere between US\$1 billion - US\$4 billion a year. Currently the market for LVADs is around US\$300 million a year. Although there are up to 10 groups with LVAD programs, the two clear leaders are Thoratec and Ventracor. Competitors that are less advanced will find it more difficult to break the market dominance that the first two or three leaders establish unless substantial improvements in performance or usability are offered.

Ventracor is well positioned to leverage from the rapid expansion of the LVAD market by Thoratec from the introduction of a more reliable heart pump. With Ventracor's product expected to reach the US market within two years, profitability for the business may coincide in a similar timeframe.

Bioshares recommendation: Speculative Buy Class B

**Bioshares** 

# FY2007-08 Profit Reviews

The Australian listed life science sector includes a number of companies that are not only securing profits but are growing profits, in some cases after many years spent developing products and developing markets.

The activities of these companies range from plasma fractionation (CSL), API manufacturing (IDT Australia), OTC and prescription pharmaceutical manufacture (Probiotec), tuberculosis diagnostics (Cellestis) and liver cancer therapy (Sirtex Medical).

Brief financial summaries and comments follow for 13 companies reporting profits for the year ending June 30, 2008.

#### ASDM – 23% lift in sales

Australian Surgical Design and Manufacture is a relatively recent listing on the ASX. The Sydney-based company designs and manufactures prosthetic implants and surgical tools. ASDM posted a modest profit for FY2008 (\$0.2 million), although the highlight was a 23% increase in sales that followed a 26% increase in the previous year.

The company is active in new product development. ASDM has manufacturing rights to the Peripheral Access Device, a device that re-pressurises blood flow, and has the potential to prevent limb amputation and also be used in cardiac bypass surgery. The PAD has been evaluated in ten patients to date.

#### Cellestis – Posts maiden profit

Cellestis recorded a maiden profit of \$2.26 million after posting sales of \$18.8 million. The Cellestis technology was initially developed at the CSIRO and then incubated at CSL. The TB diagnostic technology was shifted into the Cellestis vehicle by founders Tony Radford and Jim Rothel in November 2000.

FY2008 was an historic year for Cellestis as it posted its first ever profit. While sales have been a long time coming, the year on year growth has been impressive. Sales rose 77% in FY2008 from the previous year. Since FY2005, sales have increased 900%. The company's high PE ratio will be tested if sales in FY2009 and FY2010 are not sustained at very high rates of growth.

#### Clover Corp – Turns the corner

Clover Corporation is a developer and manufacturer of functional foods, including a specially formulated and encapsulated fish oil product that is used in infant formula.

Clover reported sales of \$21.6 million, representing an increase of 31% from the previous year. Clover's latest profit result of \$4.14 million (up 515%) is welcome indeed, coming on the back of a lack lustre string of profit results. However, adjusted for a \$1.3 million tax benefit, net profit was \$2.8 million for the year.

Clover's growth in sales was driven by sales of infant formula additives in the Asia Pacific region. In a related development the company has signed a five year contract (and now commenced supplying) with Mead Johnson to supply 50% of its needs for HiDHA tuna oil and HiDHA Driphorm powder in product applications for children greater than 12 months of age.

ASDM			CMP	\$0.45
AMT	Cap'n (\$M)	\$16	PE	88
	FY2005	FY2006	FY2007	FY2008
Sales (\$M)	\$4.5	\$4.4	\$5.6	\$6.8
Change		-1%	26%	23%
EBIT (\$M)	\$0.64	-\$0.14	-\$0.12	\$0.29
Change		-123%	-18%	NA
Net Profit (\$M)	\$0.27	-\$0.32	-\$0.45	\$0.18
Change		-217%	42%	NA

Cellestis			CMP	\$2.19
CST	Cap'n (\$M)	\$210	PE	93
	FY2005	FY2006	FY2007	FY2008
Sales (\$M)	\$1.9	\$5.3	\$10.7	\$18.8
Change		178%	102%	77%
EBIT (\$M)	-\$3.63	-\$3.62	-\$2.28	\$2.26
Change		NA	NA	NA
Net Profit (\$M)	-\$3.35	-\$3.62	-\$2.28	\$2.26
Change		NA	NA	NA

Clover Corp	CMP	\$0.22		
CLV	Cap'n (\$M)	\$36	PE	13
	FY2005	FY2006	FY2007	FY2008
Sales (\$M)	\$14.3	\$17.3	\$16.5	\$21.6
Change		21%	-5%	31%
EBIT (\$M)	\$1.07	\$1.03	\$1.30	\$3.04
Change		-4%	26%	135%
Net Profit (\$M)*	\$0.77	\$0.45	\$0.64	\$2.80
Change		-41%	40%	341%

\* adjusted for FY08

#### Cochlear – Strong AUD weakens earnings by \$21 M

Global hearing implant manufacturer Cochlear grew sales by 8% for FY2008 and net profit by 15% for the same period. The company ascribed a negative \$21 million impact of a strong AUD over the fiscal year on the company's core earnings. (Adjusting for currency impacts, sales increased by 18%.) Sales of cochlear implants grew 5%, to \$504.5 million, whereas the sales of the bone anchored system (Baha) performed strongly, rising 21% to \$75.9 million. By region, the strongest growth occurred in Europe, up 30% in constant currency terms, followed by Asia/Pacific (up 20%) and the Americas (up 6%). Cochlear's gearing ratio fell slightly over the fiscal year, down from 31% to 29%.

Established markets' growth for cochlear implants is expected to benefit from customers who opt for a second implant, with 15%-20% of implants in those markets being for a second implant.

#### Compumedics – Sustainable profits an elusive goal

Compumedics manufactures and sells sleep and neurological diagnostic equipment. Sales improved marginally for FY2008, increasing 5% to \$38 million. Overall sales have effectively been flat for the last four years. The company turned a small profit of \$0.8 million for the year just ended.

Administration costs in the Computedics business totalled \$4.8 million for FY2008. These costs have been constant at about 13% of sales for the last four years.

The company's R&D spend for FY2008 was \$4.6 million, or 12% of sales. R&D spend has fallen markedly; in FY2005 it was \$8.9 million or 23% of sales. Significant and sustainable growth in profitability has proved an elusive ambition for Compumedics.

# Cryosite – Relocating to cater for growth

Cryosite is a company that specialises in the storage of biological products, including clinical trial tissue samples and cord blood collections.

Cryosite is a minnow of a company, capitalised at \$6 million. This company generated sales in excess of its capitalisation for FY2008, of \$6.6 million. Net profit fell 55% over the year to \$0.45 million. To cater for increases to future expected demand for its services, the company is relocating from its premises in Lane Cove to larger premises in South Granville. The company spent \$0.35 million on relocation expenses in the FY2008 period.

The company expects strong growth in clinical trials to support growth in the company's business. The company has 50 clients in the area and is associated with around 200 trials. It estimates that the number of clinical trials being conducted is between 800 and 1000 and is growing at 15% per annum.

One risk going forward with Cryosite is whether it is able to renew a five-year contract it has had with American Type Culture Collection.

Cochlear			CMP	\$53.97
СОН	Cap'n (\$M)	\$3,014	PE	26
	FY2005	FY2006	FY2007	FY2008
Sales (\$M)	\$349.0	\$452.3	\$556.2	\$600.1
Change		30%	23%	8%
EBIT (\$M)	\$85.24	\$115.23	\$153.58	\$162.63
Change		35%	33%	6%
Net Profit (\$M)	\$58.48	\$78.23	\$97.68	\$115.23
Change		34%	25%	18%

Compumedics	CMP	\$0.17		
CMP	Cap'n (\$M)	\$24	PE	31
	FY2005	FY2006	FY2007	FY2008
Sales (\$M)	\$38.4	\$37.7	\$36.7	\$38.6
Change		-2%	-3%	5%
EBIT (\$M)	-\$4.68	-\$1.60	\$0.99	\$1.40
Change		NA	NA	41%
Net Profit (\$M)	-\$4.68	-\$1.60	\$0.12	\$0.76
Change		NA	NA	515%

Cryosite			CMP	\$0.13
CTE	Cap'n (\$M)	\$6	PE	14
	FY2005	FY2006	FY2007	FY2008
Sales (\$M)	\$2.8	\$4.1	\$4.7	\$6.6
Change		45%	15%	41%
EBIT (\$M)	\$0.11	-\$0.63	\$0.38	\$0.46
Change		NA	NA	19%
Net Profit (\$M)	\$0.10	-\$0.63	\$0.99	\$0.45
Change		NA	NA	-55%

## CSL – A stellar performance

CSL, Australia's largest pharmaceutical firm and 14th largest ASXlisted company, drove a 30% lift in net profit to \$702 million, from sales of \$3.6 billion. Domestic sales of Gardasil were a significant component of this result, with local sales of \$227 million reported. Local sales are expected to decline in FY2009 as a schools-based catch up program is expected to complete by the end of CY2008. CSL expects FY2009 *sales* of Gardasil to be in the order of \$100 million. Gardasil royalties received from Merck revenues were \$167 million for FY2008. CSL expects FY2009 *royalties* for Gardasil to be in the order of \$180- \$200 million.

Sales for CSL's largest division, CSL Behring were \$2.822 billion (US\$2.5 billion), and rose 15% in constant currency terms.

CSL has now completed expansion at its Melbourne flu vaccine plant to produce 40 million doses per season (there are two per year), with the company's US branded flu vaccine Affluria now approved for sale by the FDA.

# Ellex Medical Lasers – Disappointing result

Adelaide-based Ellex Medical Lasers manufactures lasers for ophthalmic surgery. The company logged a 13% growth in sales for FY2008, with \$50.3 million achieved for the year. The company posted a net profit of \$4.8 million, but adjusted for on-offs, was \$1.1 million (previous year – \$4.4 million and adjusted \$2.5 million). The 'one-offs' related to deferred tax assets. However, the company was disappointed with the result, and especially that its investment in sales and marketing activities in the US did not pay off to the degree expected. US sales increased 10%, in contrast to sales growth in Australia (36%), Japan (25%) and Europe (17%). The company also suggested that the credit crisis had a negative impact on the short term buying decisions of its customers.

Ellex's employee costs increased 30%, from \$12.5 million in FY2007 to \$16 million in FY2008. Ellex now employs six direct sales staff in the USA in addition to 10 independent representatives.

#### IDT Australia – Expanding the business

IDT Australia provides services to the global drug development industry in addition to highly specialised API (active pharmaceutical ingredient) and finished dose manufacturing. Sales for FY2008 increased 18% to \$31.5 million and the company posted a net profit of \$7.1 million (+30%).

The company announced a final dividend of \$6.5 cents, which with the half year dividend of 5.5 cents has the stock offering a yield of 5.6%.

Growth prospects for the company auger well for IDT following the commissioning of 4000 litre facility developed in conjunction with Pfizer. The company expects to deliver strong double digit profit growth in FY2009.

CSL			CMP	\$39.43
CSL	Cap'n (\$M)	\$23,589	PE	34
	FY2005	FY2006	FY2007	FY2008
Sales (\$M)	\$2,609.0	\$2,848.9	\$3,172.4	\$3,556.7
Change		9%	11%	12%
EBIT (\$M)	\$432.2	\$515.0	\$918.7	\$1,108.4
Change		19%	78%	21%
Net Profit (\$M)	\$487.8	\$117.4	\$539.3	\$701.8
Change		-76%	359%	30%

Ellex Medical Las	CMP	\$0.26		
ELX	Cap'n (\$M)	\$18	PE	16
	FY2005	FY2006	FY2007	FY2008
Sales (\$M)	\$27.0	\$34.6	\$44.4	\$50.3
Change		28%	28%	13%
EBIT (\$M)	\$1.21	\$4.20	\$3.34	\$2.51
Change		248%	-20%	-25%
Net Profit (\$M)*	\$0.63	\$3.69	\$2.52	\$1.11
Change		487%	-32%	-56%

\* adjusted for FY07,FY08

IDT Australia	CMP	\$2.15		
IDT	Cap'n (\$M)	\$93	PE	13
	FY2005	FY2006	FY2007	FY2008
Sales (\$M)	\$26.9	\$25.0	\$26.7	\$31.5
Change		-7%	7%	18%
EBIT (\$M)	\$5.36	\$5.12	\$7.86	\$10.18
Change		-4%	53%	29%
Net Profit (\$M)	\$3.34	\$3.62	\$5.47	\$7.11
Change		8%	51%	30%

#### ITL Corp – A poor result

ITL Corp sells and manufactures medical devices and medical procedure kits. The company recorded sales of \$38.2 million, up 9% from the previous year. The company's profitability has slumped over the last two years, with the result for FY2008 of \$0.8 million down 56% from the FY2007, and the FY2007 result down 46% from the FY2006 figure.

Australian operations generated sales of \$15.6 million, down from \$16.7 million in FY2007. The company also said its Malaysain healthcare business was seriously impacted by the downturn in large medical infrastructure projects in Malaysia. ITL is hoping that staff cuts and new a new business information system will contribute to an improved performance.

# Probiotec – A strong result

Probiotec is a manufacturer of branded OTC and prescription products. It also provides contract manufacturing services. The company's brands include the Biosource supplements lines, the Medislim weight loss lines, the Milton antibacterial range, and the David Craig brand for pharmacy products. The company is headquartered in Laverton, but also operates facilities in Nowra, Bundaberg and Malanda.

Probiotec generated a strong result for FY2008, with sales increasing 22% to \$65.8 million. Sales in the pharmaceutical and consumer health segment rose by 43% for FY2008 (\$48.7 million). Net profit of \$6.3 million rose 27% for the period. Normalised net profit grew 60.3%. Gross profit margins increased 5.3% to 42.7%. However, the company has relatively high debt levels, with gearing at 52%.

New product development is a key plank for growth at Probiotec, with the company investing \$1.9 million in new product development in FY2008. The company employs 50 people in QC and product development and 500 people in total.

The company has signalled that it expects that net profit to grow by at least 20% in the next year.

#### Resmed – Continuous product development

Sleep-disordered breathing company Resmed generated sales of US\$835 million for FY2008, up 17% from the previous year. (Resmed is a US company that was founded in Australia (1989) and maintains manufacturing facilities in Sydney. The company's shares trade as depository receipts on the ASX.) However, when movements in US currency are taken into account sales increased by 11%.

Resmed posted a net profit US\$110 million, which represented an increase 66% from the previous year. (FY2007 results were impaired by a product recall.) Sales in North and Latin America increased 9% for the year, and sales outside these area increased by 25%. New product development is a major theme of the Resmed growth argument, with two new masks, the Micro Mirage and the Swift LT, and new instruments, the CPAP S8 Autoset II and the VPAP Auto introduced this year.

ITL Corp			CMP	\$0.09
ITD	Cap'n (\$M)	\$12	PE	16
	FY2005	FY2006	FY2007	FY2008
Sales (\$M)	\$21.2	\$31.3	\$35.0	\$38.2
Change		47%	12%	9%
EBIT (\$M)	-\$0.48	\$3.88	\$2.44	\$1.43
Change		-901%	-37%	-41%
Net Profit (\$M)	-\$0.03	\$3.26	\$1.74	\$0.76
Change		-10122%	-46%	-56%

Probiotec			CMP	\$1.35
PBP	Cap'n (\$M)	\$63	PE	10
	FY2005	FY2006	FY2007	FY2008
Sales (\$M)	\$26.0	\$41.5	\$54.0	\$65.8
Change		60%	30%	22%
EBIT (\$M)	-\$4.28	\$4.13	\$7.66	\$10.41
Change		NA	85%	36%
Net Profit (\$M)	-\$2.83	\$1.81	\$4.98	\$6.31
Change		NA	176%	27%

Resmed	CMP	\$5.41		
RMD	Cap'n (\$M)	\$4,186	PE	32
	FY2005	FY2006	FY2007	FY2008
	US\$	US\$	US\$	US\$
Sales (\$M)	\$425.5	\$607.0	\$716.3	\$835.4
Change		43%	18%	17%
EBIT (\$M)	\$97.43	\$132.07	\$104.45	\$167.91
Change		36%	-21%	61%
Net Profit (\$M)	\$64.79	\$88.21	\$66.30	\$110.30
Change		36%	-25%	66%

# Sirtex Medical – Marketing costs impact bottom line

Sirtex Medical markets Sir-Spheres, a treatment for liver cancer. After reporting strong growth in sales for FY2007 (+48%, \$33 million), growth fell back in FY2008 to 14%, with an end year result of \$38 million. Appreciation of the AUD against the USD impacted Sirtex's sales, which increased 22.5% on a volume basis.

Sirtex's profit fell 23%, with the company increasing marketing costs from \$9.8 million in FY2007 to \$16 million in FY2008.

Sirtex expects costs in the order of \$5.5 million pertaining to its litigation with UWA and Dr Bruce Gray to be recovered. It is uncertain when this recovery might take place. The company held cash of \$7 million at the close of the financial year and was essentially debt-free.

#### Summary

Not covered were Arana Therapeutics, which has a September 30 end of financial year and SDI, Blackmores and Medical Developments. In short, 17 profitable life science companies are listed on the ASX.

Some companies moving towards profitability include Biota Holdings, Cogstate, Atcor Medical, Acrux, Labtech Systems and Somnomed.

**Bioshares** 

Sirtex Medical	CMP	\$2.20		
SRX	Cap'n (\$M)	\$123	PE	101
	FY2005	FY2006	FY2007	FY2008
Sales (\$M)	\$11.8	\$22.6	\$33.3	\$38.1
Change		91%	48%	14%
EBIT (\$M)	-\$1.99	\$5.46	\$4.33	\$2.50
Change		NA	-21%	-42%
Net Profit (\$M)	-\$2.00	\$1.81	\$1.57	\$1.21
Change		NA	-13%	-23%

# Tissue Therapies – A Positive Result

Tissue Therapies (TIS: SP 13 cents; Cap \$5 M) has delivered the first result from a clinical treatment using its wound healing technology, Vitrogro. One patient who had a venous leg ulcer that had not been healing for several months experienced a 60% reduction in the wound area within 21 days, after only four applications of the Vitrogro product. It was a spectacular result and consistent with preclinical studies.

Not only was there a large reduction in the immediate wound size, but the surrounding area clearly looked to have improved.

The issue for Tissue Therapies is how it will commercialise the technology. Clinical trials in Canada (in 30 patients) were expected to start last year and the company is still awaiting approval to proceed from Health Canada. In the meantime the company is conducting a clinical trial in Australia in eight patients, which is expected to be completed by year's end.

The appeal of gaining approval in Canada is that there is mutual recognition with other regulators, including the TGA in Australia and most of Europe. However it appears that quite a few other groups are following a similar pathway, a possible explanation for the regulatory delay from Canada to proceed with trials.

Whilst the technology is compelling, the company is constrained by its access to funding. We estimate the company will have just over \$1 million following the recently completed share purchase

Company	Price (current)	Price added to portfolio	Date added
Impedimed	\$0.75	\$0.70	Aug-08
Antisense Therapeutics	\$0.07	\$0.07	Aug-08
Mesoblast	\$1.14	\$1.25	Aug-08
Avexa	\$0.29	\$0.32	Jun-08
Cellestis	\$2.19	\$2.27	April 2008
IDT	\$2.15	\$1.90	March 2008
Circadian Technologies	\$0.83	\$1.03	February 2008
Patrys	\$0.25	\$0.50	December 2007
NeuroDiscovery	\$0.09	\$0.16	December 2007
Bionomics	\$0.35	\$0.42	December 2007
Cogstate	\$0.14	\$0.13	November 2007
Sirtex Medical	\$2.20	\$3.90	October 2007
Clinuvel Pharmaceuticals	\$0.29	\$0.66	September 2007
Starpharma Holdings	\$0.24	\$0.37	August 2007
Pharmaxis	\$2.32	\$3.15	August 2007
Universal Biosensors	\$0.78	\$1.23	June 2007
Biota Holdings	\$0.78	\$1.55	March 2007
Probiotec	\$1.35	\$1.12	February 2007
Peplin Inc	\$0.45	\$0.83	January 2007
Arana Therapeutics	\$1.11	\$1.31	October 2006
Chemgenex Pharma.	\$0.93	\$0.38	June 2006
Cytopia	\$0.22	\$0.46	June 2005
Optiscan Imaging	\$0.23	\$0.35	March 2005
Acrux	\$1.10	\$0.83	November 2004
Alchemia	\$0.30	\$0.67	May 2004

plan. The company is looking at raising additional funds from sophisticated investors.

The wound healing market is massive. However, the challenges for a small biotech with very limited cash resources to access this market are becoming obvious. Tissue Therapies will need to license the technology or merge with a larger group to gain greater leverage.

Bioshares recommendation: Speculative Buy Class C

**Bioshares** 

# Portfolio Changes – 5 Sept 2008 IN: No changes.

**OUT:** No changes.

279

<pre>rine purpose of valuation, <i>Micobarre</i> divides biotech stocks in on categories. The first group as socks with existing positive cash flows, The second group are stock with une nare morpositive cash flows. The second group, which are essen- tiative risk within that group to better reflect the very large speci ative risk within that groups to better reflect the very large speci interview teach flows excess.</pre> Sock with positive cash flows of close to producing positive cash flow scokes. Sock with the more stocks. Sock within the group to better reflect the very large speci interview teach flows or close to producing positive cash flows in the second group are stock within those stocks. Soc CMP is 20% - Fair Value Soc Market Prices The Value Sock and Price Cash sock may have more than one technology, product of more within those stocks. Soc CMP is 20% - Fair Value Sock may have more than one product or opportunity, and were not close to and may need streamgenesing. Sociellating Bug - Class B These stocks group thare more than one product or opportunity, and were not close to and may need streamgenesing. Sociellating Bug - Class A These stocks group thare more than one product or opportunity, and were not close to and may need streamgenesing. Sociellating Bug - Class A These stocks group thare more product in development and lack may external validation features. Speculating Bug - Class A These stocks group thare more product in development and lack may external validation features. Speculating Bug - Class A These stocks group thare more product or opportunity, and second and may need streamgenesis. Speculating Bug - Class A These stocks group thare more product in development and lack may external validation features. Speculating Bug - Class A The stocks represent the stock is relative second may need streamgenesis. Speculating Bug - Class A These stocks stocks may have more than one product or opportunity, and second stream validation features. Speculating Bug - Cl	<pre>or the purpose of valuation. <i>Bioshares</i> divides biotech stocks in which groups are stocks without near term positive cash flows. This second group are stocks or at early sugges commercialisation. In this second group, which are essentially assessed or the properties of the second group are stocks. <i>Second Structure</i> <b>Bios</b>. <b>Class A</b> </pre>	shares	Number 279 – 5 September 2008	Page 10	
<pre>or descriptions: The first group are stacks with existing positive call hows. In second group within the second group wit</pre>	<pre>crucies. The first propage are stocks with existing positive cash flows. The second group with the exist flow tenter term positive cash flows. The second group with the exist ity speculative propositions. <i>Bioshares</i> grades them according there is within those stocks.</pre>	w Biosh	ares Rates Stocks	Group B	
Induction terms positive cash flows, history of losses, or at early ges of commercialization. In this second proop, which are essentially operative propositions, <i>Biocharres</i> grades them according there risk within thrage root, to better reflect the very large specialized in the proop of the second proop, which are essentially and the proop of the second proop, which are essential that proop, to better reflect the very large specialized in the proop of the second proop, which are essential that proop, to better reflect the very large specialized in the second proop of the second proop, which are essential to the provide the reflect the very large specialized in the second proop of the s	hour nerrem 'positive cash flows, history of losses, or at early ge of commercialisation. In this second group, which are essentive speculative propositions, <i>Bioshares</i> grades them according on their risk within those stocks.       Speculative <i>Dup</i> -Class <i>A</i> outp A       Hease stocks with existing positive cash flows or close to producing positive cash in the group, to better reflect the very large special direct the stock is relative less risks than other biotech stock speculative <i>Dup</i> -Class <i>B</i> outp A       Hease stocks with existing positive cash flows or close to producing positive cash is a very less relative. Hease stocks may have more than one product or opportunity, may even be close to market. However, they are likely to be line several key area below to be and the resonance of submerse. For example, their cash position is weak, management or board may need strengthening.         option CMP is 10% < Fair Value	or the purpose of valuation, <i>Bioshares</i> divides biotech stocks into o categories. The first group are stocks with existing positive cash flows		Stocks without near term positive cash flows, history of losses, or at early stages commercialisation.	
<pre>sp of commercialisation. In this second group, which are essent by speculative propositions, <i>Biochemisers</i> grades them eccording to be six within those stocks.</pre>	<pre>ses of commercialisation. In this second group, which are essent by specializity propositions, <i>Bioichardians</i> grands them according to itive is is within those stocks.</pre> The stocks will have more than one technology, product or prop A dis within those stocks. The stocks will have more than one technology and scientific advisory bas index rates with existing positive cash flows or close to producing positive cash the stocks with existing positive cash flows or close to producing positive cash the stocks with existing positive cash flows or close to producing positive cash the stocks with existing positive cash flows or close to producing positive cash the stocks with existing positive cash flows or close to produce the stock is relative less risky than oher biotech stock Speculative Bud <i>P - Class T</i> These stocks may have more than one product in development, with you cone product in development, with you cone the stocks is relative less risky than oher biotech stock Speculative Bud <i>- Class A or B or C</i> Seculative Bud <i>- Class A or B or C</i> Seculative Ender <i>- Class A or B or C</i> Seculat			Speculative Buy – Class A	
<pre>side is it within frag group, to better reflect the very large spread is within those stocks. Sup A A deviation of the intermediation of the intermed</pre>	within the group, to better reflect the very large special is within those stocks.       offering multiple opportunities. These features, coupled to the presence of alliances, patremethysis and scientific advisory boa indicate the stock is relative less risky multiple.         Spe A       Swith existing positive cash flows or close to producing positive cash flows or close to produce program.       The stocks may have more than one product or opportunity, may even be close to market. However, they are filled by to be line several key areas. For example, their cash position is weak, management or board may need strengthemic.         Produced WMAR Price       CMP is 20% < Fair Value				
<pre>site within those stocks. prove A ske within those stocks can be a composition of the stock stocks. prove A ske within those stocks. prove A ske</pre>	<pre>isk within those stocks.</pre>			· · · ·	
mp A         chewith existing positive cash flows or close to producing positive cash         manuality       CMP is 20% < Fair Value	<pre>indicate the stock is relative less risky than other biotech stock product or opportative sets is the stock is relative less risky than other biotech stock product or opportation product or opportation is several key areas. For example, their cash position is weak, management or board may need strengthening. product or opportation product or opport product or opportation product or opport product or oppor</pre>				
ackwith existing positive cash flows or close to producing positive cash       These stocks may have more than one product or opportunity, and may even be close to market. However, they are likely to be lacking in several key areas. For example, their cash position is weak, or management of board may need strengthening. Speculative Super Class St or Barket, However, they are likely to be lacking in several key areas. For example, their cash position is weak, or management of board may need strengthening. Speculative Star Data Strengthening.         Very Law 2006 CFMP is	is with existing positive cash flows or close to producing positive cash       These stocks may have more than one product or opportunity, may even be close to market. However, they are likely to be to be in several key areas. For example, their cash position is weak, mangement or board may need strengthening.         ymmate       CMP is 20% < Fair Value	isk within	nose stocks.	indicate the stock is relative less risky than other biotech stocks.	
may even be close to market. However, the yare likely to be lacking in several key areas. For example, their cach position is weak, or management or board may need strengthening.         y       CMP is 20% < Fair Value	ask       may even be close to market. However, they are likely to be la         in several key areas. For example, their cash position is weak,         main general key areas. For example, their cash position is weak,         main general key areas. For example, their cash position is weak,         main general key areas. For example, their cash position is weak,         main general key areas. For example, their cash position is weak,         may even be close to market. However, they are likely to be la         in weak, and the example, their cash position is weak,         main general key areas. For example, their cash position is weak,         may even be close to market. However, they are likely to be la         in weight is 20% > Fair Value         may even be close to market. However, they are likely to be la         in weight is 20% > Fair Value         proported Subscribers:         phylogica, Pharmaxis, NeuroDiscovery, Biotech Capital, Cytopia, Arnan Therapeutics, Star         didings, Cogstake, Xeed Biotechnology, Optiscan Imaging, Bioometics, ChemGenex Pharmaceuticals, Circadian Techno         teams:         transfer to event the event set of	-	cting positive each flows or close to producing positive each		
y       CMP is 20% < Fair Value	y       CMP is 20% < Fair Value		sung positive cash nows or close to producing positive cash	may even be close to market. However, they are likely to be lacking	
intermediate       CMP is 10% < Fair Value	camulate       CMP is 10% < Fair Value				
ind       Value = CMP       These stocks generally have one product in development and lack generally have can be product in development and lack generally have can be product in development and lack generally have can be product in development and lack generally have can be product in development and lack generally have can be product in development and lack generally have can be product in development and lack generally have can be product in development and lack generally have can be product in development and lack generally have can be product in development and lack generally have can be product in development and lack generally have can be product on the product and an other product pr	idia       Value = CMP       These stocks generally have one product in development and I many external validation features.         idia       CMP is 10% > Fair Value       Speculative II.01 - Class A or B or C.         MP_Current Market Price)       Sett         Orporate Subscribers:       Phylogica, Pharmaxis, NeuroDiscovery, Biotech Capital, Cytopia, Arnan Therapeutics, Star II.01         holdings, Cogstate, Xceed Biotechnology, Optiscan Imaging, Bionomics, ChemGenex Pharmaceuticals, Circadian Techno to tholdings, Stem Cell Sciences, Halcygen Pharmaceuticals, Peplin, BioMD, Impedimed, QRxPharma, Patrys, Labtech stems, Hexima, Proteome Systems         istainer       formation contained in this newletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates breines inclammed biodevice, financial statuto and patiential metal machanys by Little (MAN) and any of their associates, officer no staff m terests in sociate on brein (Corporations Law & 849). Details contained herein have been provide big that for the parado any pre- many since thermany of the currency is given and percoss science of the onitation provide big that for the parado any pre- secure of the investment advector is given and percoss science of the investment advector in development enquites.         formation herein is contained to the science of the particular metal. Acaita and the investment advector is given and percoss science of the analytic investment advector is advected to analytic investment advector is given and percoss science of the investment advector and advector is advected to advect the one variation of the particular percoss conscience of the investment advectore advectore is advected on the basis they areally fore	•			
March 200% > Fair Value       Speculative Hold - Class A or B or C         March 2007       Self         Orporate Stubscribers:       Phylogica, Pharmaxis, NeuroDiscovery, Biotech Capital, Cytopia, Arana Therapeutics, Starphara bidings, Cogstate, Xceed Biotechnology, Optiscan Imaging, Bionomics, ChemGenex Pharmaceuticals, Circadian Technologie to a Holdings, Stem Cell Sciences, Haleygen Pharmaceuticals, Peplin, BioMD, Impedimed, QRxPharma, Patrys, Labtech stems, Hexima, Proteome Systems         Istainar:       Itomation contained in this newletter is not a complete analysis of every material fact respecting any company, industry or security. The options and estimates herein expressed treas sciences or self my bare factore press of the phylocytane mech. Acade Stabis Distaine on the analysis Pt J Ldt (BMA) and any of their sociates of there is or and my bare treas sciences of the phylocytane mech. Acade Stabis Distaine on the analysis of every material fact respecting any company, industry or security. The options and estimates herein expressed treas sciences or and my bare bare sciences or and my bare bare bare presson treas sciences or and there analysis Pt J Ldt (BMA) and any of their associates of decine interests in the following ASX Healtheare and Biotechnology to respensive commendation to the ace sciences or and finance and associates decine interests in the following ASX Healtheare and Biotechnology or company industry on sciences and there analysis Pt J Ldt (BMA) and any of their associates decine interests in the following ASX Healtheare and Biotechnology science sciences and there analysis Pt J Ldt (BMA) and any of their associates decine interests in the following ASX Healtheare and Biotechnology science sciences aneal sciences and cassope	CMP is 20% > Fair Value         Speculative Hold - Class A or B or C         Set         MP-Current Market Price)         Set				
MP-Current Market Price     Set       Drporate Subscribbers:     Phylogica, Pharmaxis, NeuroDiscovery, Biotech Capital, Cytopia,Arana Therapeutics, Starpharn Addings, Cogstate, Xeced Biotechnology, Optiscan Imaging, Bioomics, ChemGenex Pharmaceuticals, Circadian Technologie obta Holdings, Stem Cell Sciences, Haleygen Pharmaceuticals, Peplin, BioMD, Impedimed, QRxPharma, Patrys, Labtech stems.       Image: constants in this ownelster is not a complete analysis of overy material fact respecting any company, industry or sectiv, The options and entities of them is expressed sections:     The options and any the price sections of them is expressed to respect the company difference of the phylication of this report balay and sections: a containing their investment advise of overy material fact respecting any company, industry or sectiv, The options and on thav respect to space, Bide Industry and Market Analysis PL at MBNA and any of their associates, officers on and may been provided by Bias and repressor impleior to them phylication of this report believes there the investment adviser in the olivary in and persons science to non-avariance and publication of this report believes the advise due to the basis they are only for the particular person or company to whom they have been provided by Bias Industry and Market Analysis PL dat.       Try, MEP, PLAP, PL	MP-Current Market Price)       Śelt         DrpOrdt S UbScribers:       Phylogica, Pharmaxis, NeuroDiscovery, Biotech Capital, Cytopia, Arana Therapeutics, Starkings, Cogstate, Xeced Biotechnology, Optiscan Imaging, Bionomics, ChemGenex Pharmaceuticals, Circadian Techno ta Holdings, Stem Cell Sciences, Haleygen Pharmaceuticals, Peplin, BioMD, Impedimed, QRXPharma, Patrys, Labtech stems, Hexima, Proteome Systems         selaire:       information contained in this newdetter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates herein expresent the current judgement of the publisher and are subject to change. Black Industry and Market Analysis Pp Ltd (BIMA) and any of their associates, offences or saffin markets in securits bein sourced to basis they aroon judgement of the publisher and are subject to change. Black Industry and Market Analysis Pp Ltd (BIMA) and any of their associates or implied contains there is a source soft the particular metha. Accordingly, inorcepients should rely on any recommendation (whether express or implied) contains there is a source soft the particular previous activation provided here is about any and market analysis Pp Ltd (BIMA) and publication of their perparation and analysis Pp Ltd (BIMA) and publication of their perparation and analysis Pp Ltd (BIMA) and publication of their perparation and analysis Pp Ltd (BIMA) and publication of their perparation and analysis Pp Ltd (BIMA) and publication of their perparation and analysis Pp Ltd (BIMA) and publication of their perparation and analysis Pp Ltd (BIMA) and publication of their perparation and analysis Pp Ltd (BIMA) and publication of their specific contains the analysis Pp Ltd (BIMA) and publication of their perparation and analysis Pp Ltd (BIMA) and publication of their perparation and analysis Pp Ltd (BIMA) and Addresses (BIMA) publications within SS				
Iddings, Cogstate, Xceed Biotechnology, Optiscan Imaging, Bionomics, ChemGenex Pharmaceuticals, Circadian Technologie tota Holdings, Stem Cell Sciences, Haleygen Pharmaceuticals, Peplin, BioMD, Impedimed, QRXPharma, Patrys, Labtech stems, Hexima, Proteome Systems         Imaging contained in this newsletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates here in expressed present charmed judgement of the publisher and are usable: to change. Blake Industry and Market Analysis PL (2014) and any of their associates, officers or staff may have treates to herein (Corporations Law s.89). Details contained herein have been provided to responsible for the paration and publication of this report herein function and provide and provide therein should may and are not additional prevents on information provided herein should may and accurate but on warranty of accuracy is given and presons scheding by any recomparation and publication of this report herein functions and publication of this report herein function and provide therein should may are not additional tector and provide therein should may are not additional recommendation (Whether appears of the paratice) and any other associates, different environs of any associates detar in there is in the following start and three and state to an additional recommendation. Flokings in stocks valued at less than \$100 are not excluded.         Visuad 2000       For multiple email distributions within \$550       2.3 email addresses pricing structure is as follows:         System 2000       For multiple email distributions within \$250       1.4 email addresses pricing structure is as follows:         Pass PLI, PAS, PLI, P	bidings, Cogstate, Xceed Biotechnology, Optiscan Imaging, Bionomics, ChemGenex Pharmaceuticals, Circadian Techno         bidings, Stem Cell Sciences, Haleygen Pharmaceuticals, Peplin, BioMD, Impedimed, QRXPharma, Patrys, Labtech         stems, Hexima, Proteome Systems         "formation contained in this newsletter is not a complete analysis of every material fact respecting any company, industry or security. The options and estimates hereines present the current judgement of the publisher and area subject to change. Blak Industry and Markt Analysis Pt Lid (BIMA) and any of their associates, officers or staff         formation beenis accurate but be varial visation approximate in the particular person accompany investment adviser (Corporations Law s.89). Details contained herein have been prepared for general investment adviser (Corporations Law s.89). The persons involved in or responsible for the repearation and publication of this report beliformation herein is accurate but be varianty of accurace j gives and persons seeking for ety on information previded herein have been provided berlin should mark that varia with entrore with dependent equities, and in the basis they are only for the particular person accompany to whom they have been provided by Blake Industry and Market Analysis Pt I teretors and area social addresses and in the basis they are only for the particular person accempticate section and variant the analysis of the same business cost centre, our \$\$50, 2-3 email addresses [bit same Black Blake Industry and Market Analysis Pt I teretors and associal section in the shawe been provided herein have been provide herein have been provided herein have been provided			-	
Iddings, Cogstate, Xceed Biotechnology, Optiscan Imaging, Bionomics, ChemGenex Pharmaceuticals, Circadian Technologie tota Holdings, Stem Cell Sciences, Halcygen Pharmaceuticals, Peplin, BioMD, Impedimed, QRXPharma, Patrys, Labtech stems, Hexima, Proteome Systems         Schimer       Imaging in this newsletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates here in expressed present the current judgement of the publisher and are usable to change. Black Industry and Market Analysis Pt (2014) and any of their associates, officers or staff may have treated to berein (Corporations Law s.89). Details contained herein have been provided therein should made there express on implete on any security of any error. Is on import is security but consulting their investment adviser (Corporations Law s.89). Details contained therein have been provided therein should made there express on implete corporation and publication of this report helicev the formation herein is accurate but on warrany of accuracy is given and presons scheding or they anterial metals. Accuracy Market Analysis Pt Ldt. The forecase and maximal presents is the following Staf Nethaltaea and Biotechnology exerts sectifics. AdJ, ACL, ACR, BLS, BTT, CSC, XCD, CTU, VCLS, SHL, TT, WIP, PAB, PLI, PXS, SHC, SPT, TTS, UBL. These interests can change at any time and are not additional recommendations. Holdings is stock valued at less than \$100 are not eveloaded.         To subscribe, post/fax this subscription form to:       Bioshares         Bioshares       De Box 193 Richmond VIC 3121         Eas: 613 93220 33350       Ienclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or         Please charge my credit card \$ MasterCard Visa       Visa	Idings, Cogstate, Xceed Biotechnology, Optiscan Imaging, Bionomics, ChemGenex Pharmaceuticals, Circadian Techno         tota Holdings, Stem Cell Sciences, Haleygen Pharmaceuticals, Peplin, BioMD, Impedimed, QRXPharma, Patrys, Labtech         stems:         terms:         formation contained in this newsteries in to complete analysis of every material fact respecting any company, industry or security. The options and estimates here is expressent the current bigdeness of the publisher and are subject to change. Blake Industry and Market Analysis Pt Lid (BMA) and any of their associates, officers or staff         report the current objectives, financial situation and particular peess. Accordingly, on creptions should provide the preparation and publication of this report bill formation herein is accurate but to varianty of accuracy is given and person seeking to rely on information provided herein should much their ow independent equities, statin Adhere is minepide and their without consulting their investment adviser (Corporations Law s.481). The persons involved in or responsible for the preparation and publication of this report bill formation herein is accurate but to varianty of accuracy and Staff Editabare and Stote Schology sector securities. Addit Changes State Herein should much their ow independent equities, and in the basis they are only for the particular person accompany to whom they have been provided herein should much their ownether stores in the following as the fact there and their own independent equitable sectors adviser and their own independent equitable sectors adviser and their own independent equitable sectors.         Interest in the following ASY fedifiberation and both the basis they are only for the particular person accuracy in they have been subore independent equitable sectors. <t< td=""><td>orporate</td><td>Subscribers: Phylogica, Pharmaxis, Neuro</td><td>Discovery, Biotech Capital, Cytopia, Arana Therapeutics, Starpharm</td></t<>	orporate	Subscribers: Phylogica, Pharmaxis, Neuro	Discovery, Biotech Capital, Cytopia, Arana Therapeutics, Starpharm	
<pre>stems, Hexima, Proteome Systems isclams: formation contained in this newsletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates herein expressed present the current judgement of the publisher and are subject to change. Blake Industry and Market Analysis Pty Ldt (BMA) and any of their associates, officers or staff may have resent is necurities referred to herein (Corporations Law 8: 831). The persons involved in or presson's to may mary investment adviser (Corporations Law 8: 831). The person's notively on any recommatation (whether express or implied) contained herein have been previousled by their associates due to basis they are only for the particular person are on subject to change. Black Industry and Market Analysis Pty Ldt (BMA) formation berein is accurate but no warranty of accuracy is given and person seeking to rely on information provided by their Analysis Pty Ldt. The formation herein is accurate but no warranty of accuracy is given and person seeking to rely on information provided by their Analysis Pty Ldt. The formation herein is accurate but no warranty of accuracy is given and person are more accurate when the even prevised by the information and publication of this report herein expressed for and/or associates declare interests in the following ASX Healthcare and Biotechnology sector securities. AtH, ACL, ACR, BLS, BTA, CGS, CXD, CYT, CLY, CXS, HXL, MBP, PAB, PLJ, PXS, SHC, SPL, TIS, UBI. These interests can change at any time and are not additional recommendations. Boldings in stocks valued at less than \$100 are not accord with the provided by their addresses by pricing structure is as follows: Subscribe, post/fax this subscription form to: Bioshares Differs and person accurate the provided by Blake Industry and Amarket Analysis Pty Ltd, or Please change my credit card \$ MasterCard Visa Gard Number Gard Number Gard Number Market Card Numbe</pre>	statistic         isolatistic         formation contained in this news/etter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates herein expresent the current judgement of the publicher and are subject to change. Black Industry and Market Analysis Pty Loft (BMA) and any of their associates, officers or staff m treests in securities referred to herein (Corporations Law vs. 849). Determined have been previous for the preparametation (whether express or implied) contained consulting their investment advise (Corporations Law x. 849). The persons involved in or responsible for the preparametation of their port bill formation and publication and publication of their port bill formation and publication of their port bill formation and publication of their port bill formation berein is accurate but to warranty of accuracy is given and person sceleting to roly on information provided by Black Industry and Market Analysis Pty Loft (BMAC Analysis Pty, TMP, PAR, LQK, SRL, STK, CSP, CYT, CYV, CYV, CYV, CYV, CMY, TMP, PAR, PL, PXS, SHC, SPL, TTS, UBL These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 accuracy is given and person accompary is solve and person accurates deference and bill for the prelimitation switching. \$550 2-3 email addresses by pricing structure is as follows:         To subscribe, post/fax this subscription form troit       Biosharese Provement Vision and Publication and Publication and Publication and Publication accurates defere interests in the pay and person accurates and person accurates and person and metations. Holdings in stocks valued at less than \$100 accuracy is given any time and are not additional recommendations. Holdings in stocks valued at less than \$100 accuracy is pricing structure is as follows:         St	-			
Installance: Information contained in this newsletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates here in spresses the current judgement of the publisher and are subject to change. Blake Industry and Market Analysis Pty Lid (BIAA) and any of their associates, officers or staff may have terests in securities referred to here in: (Corporations Law s.851). The persons involved to or responsible for the preparation (whether expresses or implied) contained in this report believe the formation here in a currant by an ownarrady of accuracy is given and persons seeking to responsible for the preparation (whether expresses remiplied) contained. The persons involved to or responsible to the preparation (whether expresses remiplied) contained in this report believe the formation here in a currant by an ownarrady of accuracy is given and persons seeking to rely on information (whether expresses remiplied) contained. Believe that the beat in the person is contained to person involved there in have beat may any industry on any tercommendations. And there is have the part on the person involved there in have done in the person is been prepared for generation (whether expresses remiplied) contained. Believe in the person involved there in have done and publication of this report believe the origon of the publisher and are subject to change. The person involved to more there ment expresses the same duration and are contained in this report believe the responsibility on any tercommendations. However, is given and prevention and are the additional recommendations. However, and person is observer to an information believes the same business contained in the intervention of the publisher and are subject to change any time and are to additional recommendations. Holding in stock valued at less than \$100 are not released.  Description for the publisher and are subject to change any time and are not additional recommendations. Folding in stock valued at less	Idealine: Information contained in this newsletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates herein ices present the current indegement of the publisher and are subject to change. Blake Industry and Market Analysis Py Lid (BIMA) and any of their associates, officers or staff m information herein is accurate but no warranty of accuracy is given and persons seeking to recipionts should be they on any recommendation (whether express or implied) containe comment without consulting their investment adviser (Corporations Law s. 881). The persons involved in orresponsible for the preparation and publication of this report their information herein is accurate but no warranty of accuracy is given and persons seeking to rely on information (whether express or implied) information herein is accurate but no warranty of accuracy is given and persons seeking to rely on information (Nether expresses or implied) information herein issued on the basis they are only for the particular person or company to whom they have been provided by Blake Industry and Market Analysis Py Lt PXS, SHC, SPL, TIS, UBL. These interests an change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 isclosed. <b>Subscription Ratess (int. GST)</b> 48 issues per year (electronic distribution): <b>\$320</b> For multiple email distributions within \$550 2-3 email addresses pricing structure is as follows: \$950 6-10 email addresses pricing structure is as follows: \$950 6-10 email addresses  To subscribe, post/fax this subscription form to: Bioshares PO Box 1933 Richmond VIC 3121 Fax: 613 93229 3350  I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$ MasterCard Visa  Card Number Signature Karden Visa Name Organisation Ph ( )			ls, Peplin, BioMD, Impedimed, QRxPharma, Patrys, Labtech	
formation contained in this newsletter is not a complete analysis of every material fast respecting any company, investments. The pointions and estimates berein expresses for expression to every the publisher and are subject to change. Black haddstry and Market Analysis PV Lud (BMA) and way of their associates, officero or star ways to expression to be every formation berein have been prepared for generation and publication of this report believe the investment adviser (Corporations Law s.89). The persons involved in or responsible for the preparation (whether expression independent enquines). Determines the term involved in a cresponsible for the preparation (whether expression independent enquines). Determines are the term involved to the stress or infelled or outper solution on provided by thats latitatry and Market Analysis PV Lud (BMA) and mate that oron and prepared for generation (whether expression independent enquines). Determines are not adviser considered by thats independent enquines). Determines are the previous as SMI to the previous independent enquines. Determines are the previous as SMI to the previous adviser to analysis of expressions and expressions as the previous information tervies. Determines are to additional recommendations. Holdings in stocks valued at less than \$100 are to response by the previous information tervies. Determines are transported in the previous information tervies. Determines are to a soluto	information contained in this news/etter is not a complete analysis of every material fact respecting any company, induced with the prediction and estimates been in the prediction of the preparation and point of an social set of the preparation and point of an social set of the preparation previde be previded by previde of an or preparation previde be previded by previde prevides of prevides of prevides and p	stems, Hex	tima, Proteome Systems		
<form></form>	present the current judgement of the publisher and are subject to change. Blake Industry and Market Analysis PyL (10)(MA) and any of their associates, officers or suff mineres is nectroic consulting their investment objectives, financial situation and particular needs. Accordingly, no recipients should rely on any person situation on the basis tesp are only of their answer beer persons involved there in should make their own independent enquirises, there are not additional recommendation (whether express or implied) containe test is accurate but no warranty of accuracy is given and persons seeking to rely on information provided berein should make their own independent enquirises, the most been issued on the basis tesp are only for the particular person or company to whoth mer paravito and publication of third sereports and advertex persons involved berein should make their own independent enquirises, the subscription berein is accurate is subjectives, financial situation and persons involved in the parts been provided by Blake Industry and Market Analysis PyL itercors and/or associates declare interests in the following ASX Healthcare and Biotechnology sector securities - AAH, ACL, ACR, BLS, BTA, CCS, CXD, CYT, CUY, CYD, CYD, CYD, CYD, CYD, CYD, CYD, CY		tained in this newslatter is not a complete analysis of every material fo	oct respecting any company, inductry or security. The opinions and estimates herein expressed	
<pre>mpmprise investment objectives, financial strainton and particular needs. Accordingly, to recipiratis should rely on any recommendation (whether express or implied) contained in this empmont without oresonability their investment advises. ASI). The persons involved in or responsible for the perparation and publication of this report believe the formation berein is accurate but no warranty of accuracy is given and persons seeking to rely on information provide herein should make their own independent enquires. Details independent herein basis they are only for the particular person or company to whom they have been provided by plate Industry and Market Analysis PPU.d. The record and/or associates declare interests in the following ASS Healthcare and Biotechnology sector securities: AASI, The PAR, PLI, PXS, SHC, SPT, TIS, UBI. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 are not address of the provide the provide declare interests in the following ASS Healthcare and Biotechnology sector securities: AASI, The PAR, PLI, PXS, SHC, SPT, TIS, UBI. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 are not address of the provide declare interests in the following ASS Healthcare and Biotechnology sector securities: AASI, The PAR, PLI, PXS, SHC, SPT, TIS, UBI. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 are not sectored with the provide declare interests in the following ASS Healthcare and Biotechnology sector securities: AASI, The PAR, PLI, PXS, SHC, SPT, TIS, UBI. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 are not sectored with the provide sectored sec</pre>	<pre>mpmp 'investment objectives, financial stituation and particular needs. Accordingly, no recipients should rely on any recommendation (whether expressor implied) containe formation herein is accurate but no warranty of accuracy is given and persons sucking to rely on information provided by Blake Industry and Market CA analysis PLL records and/or associates declare interests in the following ASX Heathcare and Blidechhology sector sector sectors. TABL ACL, BLS, BTA, CGS, CXD, CYT, VC, XX records and/or associates declare interests in the following ASX Heathcare and Blidechhology sector sectors. TABL ACL, BLS, BTA, CGS, CXD, CYT, VC, XX records and/or associates declare interests in the following ASX Heathcare and Blidechhology sector sectors. TABL ACL, BLS, BTA, CGS, CXD, CYT, VC, XX records and/or associates declare interests in the following ASX Heathcare and Blidechhology sector sectors. TABL ACL, BLS, BTA, CGS, CXD, CYT, VC, XX records and/or associates declare interests in the following ASX Heathcare and Blidechhology sector sectors. TABL ACL, BLS, BTA, CGS, CXD, CYT, VC, XX records and/or associates declare interests in the following ASX Heathcare and Blidechhology sector sectors. TABL ACL, BLS, BTA, CGS, CXD, CYT, VC, XX records and/or associates declare interests in the following ASX Heathcare and Blidechhology sector sectors. TABL ACL, BLS, BTA, CGS, CXD, CYT, VC, XX records and/or associates declare interests in the following ASX Heathcare and Blidechhology sector sectors. TABL ACL, BLS, BTA, CGS, CXD, CYT, VC, XX isode</pre>	present the cur	rent judgement of the publisher and are subject to change. Blake Indus	stry and Market Analysis Pty Ltd (BIMA) and any of their associates, officers or staff may have	
<pre>cumum without consulting their investment adviser (Corporations Law s.83). The persons involved in or responsible for the preparation and publication of this report believe the discrimentation is accurate but no varranty of accuracy is joint and persons sections period be provided by Biak Industry and Market Analysis Pt U.d. The increases and socializes believes the discrimentation in the share been bised on the basis they are only for the particular persons or company to whom they have been provided by Biak Industry and Market Analysis Pt U.d. The increases and socializes believes that biology score socializes believes that biology score socializes believes that biology score socializes believes that biology active score score increases the distributions within \$550 are not additional recommendations. Holdings in stocks valued at less than \$100 are not sclosed.           Description Rates (inc. GSE)         Commutiple email distributions within \$550 are email addresses by the same business cost centre, our \$750 4re email addresses by increases and score sc</pre>	cument without consulting their investment adviser (Corporations Law s.81). The persons involved in or responsible for the preparation and publication of this report beli formation herein is accurabe to a warray of a cocuracy is given and persons excites igo rely on information provided here in should make their own independent enquires. The person advar associates declare interests in the following ASX Healthcare and Biotechnology sector securities: AAH, ACL, ACE, BLS, BTA, CGS, CXD, CYT, CVU, CXI, TY, MBP, PAB, PLI, PXS, SHC, SPL, TTS, UBI. These interests can change any time and are not additional recommendations. Holdings in stocks valued at less than \$100 sclosed. <b>Subscription Rates (inc. GST)</b> A8 issues per year (electronic distribution): <b>\$320</b> . For multiple email distributions within \$550 2-3 email addresses the same business cost centre, our \$750 4-5 email addresses pricing structure is as follows: \$950 6-10 email addresses pricing structure is as follows: \$950 email e				
<pre>number of have been issued on the basis they are only for the particular preson or company to whom they have been provided by Black Industry and Market Analysis Pty Ldt. NHE interests in the following ASS Healthcare and Blootechnology sectors exactines: AAH, ACI, ACR, BLS, BATA, CGS, CXD, CYT, CUY, CXD, CXS, HXL, DY, MBP, PAB, PLI, PXS, SHC, SPL, TIS, UBI, These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 are not interests in the following ASS Healthcare and Blootechnology sectors exactines: AAH, ACI, ACR, BLS, BATA, CGS, CXD, CYT, CUY, CXD, CXS, HXL, DY, MBP, PAB, PLI, PXS, SHC, SPL, TIS, UBI, These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 are not interests in the following ASS Health and Blootechnology sectors exactines: AAH, ACI, ACR, BLS, BATA, CGS, CXD, CYT, CUY, CXD, CXS, HXL, DY, MBP, PAB, PLI, PXS, SHC, SPL, TIS, UBI, These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 are not inclusive interests in the following ASS Health and Blootechnology sectors exactines: AAH, ACL, ACR, BLS, BATA, CGS, CXD, CYT, CUY, CXD, CXS, HXL, DY, MBP, PAB, PLI, PXS, SHC, SPL, TIS, UBI, These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 are not inclused.</pre>	natiated herein have been issued on the basis they are only for the particular person or company to whom they have been provided by Blake Industry and Market Analysis Pyt. MBP, PAB, PLI, PXS, SHC, SPL, TIS, UBI. These interests is can change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 is known. Subscription Rates (inc. GST) 48 issues per year (electronic distribution): \$320 For multiple email distributions within \$550 2-3 email addresses the same business cost centre, our \$750 4-5 email addresses pricing structure is as follows: \$950 6-10 email addresses pricing structure is as follows: \$950 6-10 email addresses I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$ MasterCard Visa Signature Expiry date Signature Expiry date Mame Organisation Ph ( )	cument withou	ut consulting their investment adviser (Corporations Law s.851). The	persons involved in or responsible for the preparation and publication of this report believe the	
PT, MBP, PAB, PLI, PXS, SHC, SPL, TIS, UBI. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 are not isclosed.         Subscription Rates (inc. GST)         48 issues per year (electronic distribution): \$320         For multiple email distributions within \$550       2-3 email addresses         pricing structure is as follows:       \$950       6-10 email addresses         pricing structure is as follows:       \$950       6-10 email addresses         Box 193 Richmond VIC 3121       Fax: 61 3 9329 3350         I enclose a cheque for \$       made payable to Blake Industry & Market Analysis Pty Ltd, or         Please charge my credit card \$       MasterCard       Visa         Card Number       Expiry date	DT, MBP, PAB, PLI, PXS, SHC, SPL, TIS, UBI. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 isclosed.  Subscription Rates (inc. GST) 48 issues per year (electronic distribution): \$320 For multiple email distributions within \$550 2.3 email addresses pricing structure is as follows: \$950 6-10 email addresses pricing structure is as follows: \$950 6-10 email addresses PO Box 193 Richmond VIC 3121 Fax: 613 9329 3350 I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$ MasterCard Visa Card Number Expiry date Signature Expiry date Organisation Ph ( )				
Subscription Rates (inc. GST)         48 issues per year (electronic distribution): \$320         For multiple email distributions within \$50       2.3 email addresses         be same business cost centre, our       \$750       4.5 email addresses         pricing structure is as follows:       \$950       6-10 email addresses         D Box 193 Richmond VIC 3121       Eax: 61 3 9329 3350         I enclose a cheque for \$       made payable to Blake Industry & Market Analysis Pty Ltd, or         Please charge my credit card \$       MasterCard       Visa         Card Number        Expiry date	Subscription Rates (inc. GST)         48 issues per year (electronic distribution): \$320         For multiple email distributions within \$550       2-3 email addresses         the same business cost centre, our \$750       4-5 email addresses         pricing structure is as follows:       \$950       6-10 email addresses         Do subscribe, post/fax this subscription form to:       Bioshares         PO Box 193 Richmond VIC 3121       Fax: 61 3 9329 3350         I enclose a cheque for \$       made payable to Blake Industry & Market Analysis Pty Ltd, or         Please charge my credit card \$       MasterCard       Visa         Card Number       Expiry date		-		
48 issues per year (electronic distribution): \$320         For multiple email distributions within \$550       2-3 email addresses         the same business cost centre, our       \$750       4-5 email addresses         pricing structure is as follows:       \$950       6-10 email addresses         To subscribe, post/fax this subscription form to:       Bioshares         PO Box 193 Richmond VIC 3121       Fax: 61 3 9329 3350         I enclose a cheque for \$       made payable to Blake Industry & Market Analysis Pty Ltd, or         Please charge my credit card \$       MasterCard       Visa         Card Number	48 issues per year (electronic distribution): \$320         For multiple email distributions within \$550       2-3 email addresses         pricing structure is as follows:       \$950       6-10 email addresses         pricing structure is as follows:       \$950       6-10 email addresses         To subscribe, post/fax this subscription form to:       Bioshares         PO Box 193 Richmond VIC 3121       Fax: 61 3 9329 3350         I enclose a cheque for \$       made payable to Blake Industry & Market Analysis Pty Ltd, or         Please charge my credit card \$       MasterCard       Visa         Card Number		, , ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	ананананананананананананананананананан	
48 issues per year (electronic distribution): \$320         For multiple email distributions within \$550       2-3 email addresses         the same business cost centre, our       \$750       4-5 email addresses         pricing structure is as follows:       \$950       6-10 email addresses         To subscribe, post/fax this subscription form to:       Bioshares         PO Box 193 Richmond VIC 3121       Fax: 61 3 9329 3350         I enclose a cheque for \$       made payable to Blake Industry & Market Analysis Pty Ltd, or         Please charge my credit card \$       MasterCard       Visa         Card Number	48 issues per year (electronic distribution): \$320         For multiple email distributions within \$550       2-3 email addresses         pricing structure is as follows:       \$950       6-10 email addresses         pricing structure is as follows:       \$950       6-10 email addresses         To subscribe, post/fax this subscription form to:       Bioshares         PO Box 193 Richmond VIC 3121       Fax: 61 3 9329 3350         I enclose a cheque for \$       made payable to Blake Industry & Market Analysis Pty Ltd, or         Please charge my credit card \$       MasterCard       Visa         Card Number		Subscription	Rates (inc. GST)	
the same business cost centre, our pricing structure is as follows:       \$750       4-5 email addresses         To subscribe, post/fax this subscription form to:       Bioshares         PO Box 193 Richmond VIC 3121         Fax: 61 3 9329 3350         I enclose a cheque for \$       made payable to Blake Industry & Market Analysis Pty Ltd, or         Please charge my credit card \$       MasterCard       Visa         Card Number	the same business cost centre, our pricing structure is as follows:       \$750       4-5 email addresses         To subscribe, post/fax this subscription form to:       Bioshares         PO Box 193 Richmond VIC 3121         Fax: 61 3 9329 3350         I enclose a cheque for \$       made payable to Blake Industry & Market Analysis Pty Ltd, or         Please charge my credit card \$       MasterCard       Visa         Card Number				
pricing structure is as follows:       \$950       6-10 email addresses         To subscribe, post/fax this subscription form to:       Bioshares         PO Box 193 Richmond VIC 3121         Fax: 61 3 9329 3350         I enclose a cheque for \$       made payable to Blake Industry & Market Analysis Pty Ltd, or         Please charge my credit card \$       MasterCard       Visa         Card Number	pricing structure is as follows:       \$950       6-10 email addresses         To subscribe, post/fax this subscription form to:       Bioshares PO Box 193 Richmond VIC 3121 Fax: 61 3 9329 3350         I enclose a cheque for \$       made payable to Blake Industry & Market Analysis Pty Ltd, or         Please charge my credit card \$       MasterCard         Card Number				
To subscribe, post/fax this subscription form to: Bioshares PO Box 193 Richmond VIC 3121 Fax: 61 3 9329 3350 I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$ MasterCard Visa Card Number Expiry date Signature Expiry date Subscriber details Name Organisation Ph ( )	To subscribe, post/fax this subscription form to: Bioshares PO Box 193 Richmond VIC 3121 Fax: 61 3 9329 3350 I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$ MasterCard Visa Card Number Signature Expiry date Subscriber details Name Organisation Ph ( )			+····	
PO Box 193 Richmond VIC 3121 Fax: 61 3 9329 3350 I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$ MasterCard Visa Card Number Signature Expiry date Subscriber details Name Organisation Ph ( )	PO Box 193 Richmond VIC 3121 Fax: 61 3 9329 3350  I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$ MasterCard Visa Card Number Expiry date Signature Expiry date Subscriber details Name Organisation Ph ( )				
Fax: 61 3 9329 3350     I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or   Please charge my credit card \$ MasterCard   Visa   Card Number   Signature   Subscriber details   Name   Organisation   Ph ( )	Fax: 61 3 9329 3350     I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or   Please charge my credit card \$ MasterCard Visa   Card Number   Signature   Expiry date   Subscriber details   Name   Organisation   Ph ( )	To sul	bscribe, post/fax this subscription form to:	Bioshares	
I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or   Please charge my credit card \$ MasterCard   Visa	I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or   Please charge my credit card \$ MasterCard   Visa				
Please charge my credit card \$ MasterCard   Visa   Card Number   Signature   Subscriber details   Name   Organisation   Ph ( )	Please charge my credit card \$ MasterCard   Visa   Card Number   Signature   Subscriber details   Name   Organisation   Ph ( )			Fax: 61 3 9329 3350	
Card Number     Signature     Subscriber details     Name   Organisation   Ph ( )	Card Number   Signature   Subscriber details   Name   Organisation   Ph ( )				
Signature	Signature   Subscriber details   Name   Organisation   Ph ( )	Please charge my credit card \$ MasterCard L Visa L			
Subscriber details       Name       Organisation       Ph ( )	Subscriber details       Name       Organisation       Ph ( )	Card N	Number		
Name        Organisation        Ph ( )	Name        Organisation        Ph ( )	Signat	ture	Expiry date	
Name        Organisation        Ph ( )	Name        Organisation        Ph ( )	Subs	criber details		
Organisation Ph ( )	Organisation Ph ( )				
Emails	Emails	Ph (	)		
		Emails	S		